Quote:

---

Livimmune is currently evaluating the role of leronlimab in HIV cure.

However, it is not curative and requires daily adherence for life1. We believe the future of HIV treatment is long-acting injectables, and Livimmune is actively pursuing a long-acting version of leronlimab.

---

It seems that CytoDyn is intending on having a new company be in charge of the development of long acting Leronlimab and possibly even Leronlimab associated with AAV.

But I don't think Livimmune will be the name of Leronlimab, but rather the company in charge of only the long acting and HIV cure.

Part of rebranding like Cyrus was saying, but the process was initiated years ago and probably already paid for as well.

LIVI would be a cool ticker, but the right way to get 54 in Roman Numerals would be LIV. It would be incorrect to include the last "I" if LIV were the first 3 digits.